Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b 4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP). J of Skin 2024, 8 (6), s420. https://doi.org/10.25251/skin.8.supp.420.